Evidence map›Paper›PMID 42458188›Full record

ArticleDermatology and therapy2026

Chronic Spontaneous Urticaria (CSU) in Chinese Patients: Real-World Evidence of Disease Control and Treatment Patterns from the Urticaria Voices Study.

Zuotao Zhao, Yi Li, Tara Raftery, Nadine Chapman-Rothe, Pallavi Saraswat, Jessica McCarthy, Ravneet Kaur Kohli, Cristina Constantinescu, Angie Li, Guojiao You and 2 more

Abstract read
In one paragraph

Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zuotao ZhaoDepartment of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
Yi LiBeijing Health Alliance Charitable Foundation, Beijing, China.
Tara RafteryNovartis Ireland Ltd, Dublin, Ireland.
Nadine Chapman-RotheNovartis Pharma AG, Basel, Switzerland.
Pallavi SaraswatNovartis Healthcare Pvt Ltd, Hyderabad, India.
Jessica McCarthyNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Ravneet Kaur KohliNovartis Healthcare Pvt Ltd, Hyderabad, India.
Cristina ConstantinescuIpsos SA, Basel, Switzerland.
Angie LiIpsos, Shanghai, China.
Guojiao YouBeijing Novartis Pharma Co., Ltd, Beijing, China.
Ruixin TanBeijing Novartis Pharma Co., Ltd, Beijing, China.
Bin YangDermatology Hospital, Southern Medical University, Guangzhou, China. yangbin101@hotmail.com.ORCID http://orcid.org/0000-0002-7155-6079

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic spontaneous urticaria (CSU), characterized by recurring itchy wheals (hives) and/or angioedema lasting > 6 weeks without identifiable triggers, affects 1.29% of China's population. China ranks second globally in urticaria disability-adjusted life years (DALYs), thus understanding real-world outcomes is important. We hypothesized that, despite ongoing treatment, a substantial proportion of Chinese patients with CSU experience inadequate disease control and impaired quality of life (QoL), with gaps between their treatment expectations and perceived achievability of optimal control. This study assessed patient-reported burden, treatment patterns, and unmet needs in these patients.

methodsThis was a cross-sectional study using 40-min online surveys. Patients were recruited through online panels. Eligibility included adults ≥ 18 years with physician-confirmed CSU diagnosis, actively treated. Descriptive analysis was stratified by disease control and treatment type.

resultsA total of 400 patients with CSU (mean age 35.09, [SD 7.24] years; 45% female) participated; 2% reported symptom onset < 1 year pre-study, 71% between 1 and 5 years, and 27% > 5 years (mean disease duration 5.31 [SD 4.89]). On the basis of the Urticaria Control Test (UCT), 35% of participants had inadequately controlled disease (UCT < 12), whereas Patient Global Impression of Severity (PGI-S) self-assessment suggested better perceived control (92% mild/no symptoms). Most diagnoses were made by dermatologists (94%); 57% of patients reported no fixed follow‑up schedule. Among inadequately controlled patients, 90% reported sleep disturbance during exacerbations. Most patients (82%) used second-generation antihistamines; one-third used Traditional Chinese Medicine. Complete symptom control was the top treatment goal (mean importance: 8.5/10), yet only 16% believed it achievable (9% of inadequately controlled).

conclusionsOne-third of treated patients with CSU reported inadequate disease control impacting QoL. The disconnect between high priority for complete control and low perceived achievability, alongside irregular follow-ups, highlights limitations in current therapies and care delivery. These findings underscore the need for more effective treatments and structured, patient-centered management pathways to optimize CSU care in China.

Indexed as

Chronic spontaneous urticariaDisease burdenDisease controlHealthcare utilization patternsPatient-reported outcomesQuality of lifeTreatment expectationsTreatment goals

Identifiers

PMID42458188
PMCPMC13558494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.